Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is a clinical-stage company pioneering T-cell reprogramming to create cell therapies for patients with solid tumors. By employing advanced genetic and epigenetic technologies, Lyell aims to overcome major challenges in current cell-based immunotherapies, including T-cell exhaustion and lack of durable stemness. Their innovative approach has led to a robust pipeline featuring product candidates like LYL797, LYL119, and LYL845.
Lyell's product portfolio is designed to address the unmet needs in cancer treatment. LYL797 targets ROR1-positive cancers such as triple-negative breast cancer and non-small cell lung cancer, incorporating genetic reprogramming to overexpress c-Jun and epigenetic reprogramming for enhanced durability. LYL119 is another ROR1-targeted CAR T-cell therapy that uses four reprogramming technologies for sustained function and cytotoxicity. LYL845, a tumor-infiltrating lymphocyte (TIL) product, is enhanced with Lyell's proprietary Epi-R™ protocol to improve potency and durability.
Recent achievements include the FDA granting Orphan Drug Designation for LYL845 in advanced melanoma. The company's innovative Epi-R P2 manufacturing process has shown potential to reduce TIL culture time significantly. Lyell is also advancing collaborations, such as with Outpace Bio, to develop localized IL-12 activity in tumors, enhancing the efficacy of T-cell therapies.
Lyell's business strategy has been bolstered by a strong financial position, with cash reserves extending operational capabilities into 2027. Despite macroeconomic challenges, Lyell continues to focus on generating clinical data and advancing its clinical programs, aiming to deliver transformative treatments for cancer patients.
For the latest updates on Lyell Immunopharma, including their financial performance and ongoing clinical trials, visit their official website.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) reported financial results for Q4 and full year 2022, highlighting a net loss of $8.4 million for Q4 and $183.1 million for the year, but significantly increased revenue of $48.4 million for Q4 and $84.7 million for the year, up from $2.8 million and $10.7 million in 2021. The company's cash position stands at $710.3 million as of December 31, 2022, supporting ongoing clinical trials and a robust pipeline. Lyell initiated Phase 1 trials for two product candidates targeting solid tumors and presented promising nonclinical data at several conferences. The company expects initial clinical data from LYL797 and LYL845 in 2024.
Lyell Immunopharma will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 4:30 pm PT. The presentation will showcase Lyell's pipeline, including CAR T cell product candidates LYL797 and LYL845, both in Phase 1 trials, and the innovative LYL119 targeting ROR1. Key technologies will be highlighted, such as NR4A3 gene knockout and Stim-RTM for enhanced CAR T cell activity. A live webcast will be available on the company’s website with a 30-day replay.
FAQ
What is the current stock price of Lyell Immunopharma (LYEL)?
What is the market cap of Lyell Immunopharma (LYEL)?
What does Lyell Immunopharma do?
What are Lyell's main product candidates?
What recent achievements has Lyell reported?
What technologies does Lyell use in their therapies?
What is the financial outlook for Lyell?
Where is Lyell Immunopharma located?
What is Epi-R™ manufacturing protocol?
What type of cancers are Lyell's therapies targeting?
How can I get updates on Lyell Immunopharma's developments?
What is Lyell's approach to addressing T-cell exhaustion?
